

CURRICULUM VITAE
REBECCA L. HAFFAJEE

RAND Corporation
20 Park Plaza, Suite 920, Boston, MA 02116
Tel. (617) 338-2059 (b)(6)
Email: haffajee@rand.org

EDUCATION:

2016	Health Policy Evaluative Sciences & Statistics Track	Ph.D.	Harvard University Cambridge, MA
	<i>Dissertation: Evaluating Legal Interventions Designed to Improve Behavioral Health Outcomes</i> <i>Committee: Michelle Mello (Co-Chair), Alan Zaslavsky (Co-Chair), Frank Wharam, Glenn Cohen</i>		
2006	Law	J.D.	Harvard Law School Cambridge, MA
2006	Law and Public Health	M.P.H.	Harvard School of Public Health Cambridge, MA
2002	Women's Studies Program Certificate in Health Policy	B.A.	Duke University Durham, NC

LICENSURE AND CERTIFICATION:

2006-	Massachusetts State Bar
2009-12	District of Columbia Bar (voluntarily left because not practicing in jurisdiction)

ACADEMIC APPOINTMENTS:

2016-19	Assistant Professor, Department of Health Management and Policy, University of Michigan School of Public Health
2019-	Adjunct Assistant Professor, Department of Health Management and Policy, University of Michigan School of Public Health
2019-	Policy Researcher, RAND Corporation

HONORS AND DISTINCTIONS:

2018	Theodore R. LeBlang Distinguished Lectureship in Law & Medicine, Southern Illinois University School of Medicine, Springfield, IL
2017	AcademyHealth Outstanding Dissertation Award at the 2017 Annual Research Meeting, New Orleans, LA
2017	Walter J. McNerney Research Award, Department of Health Management and Policy, University of Michigan School of Public Health
2017	Health Policy Grand Rounds Seminar Speaker, Richard M. Fairbanks School of Public Health, Indiana University
2015	AcademyHealth Student Poster Award at the 2015 Annual Research Meeting, Minneapolis, MN

2015	Joan P. Curhan Citizenship Award for the Ph.D. Program in Health Policy, Harvard University
2013-14	Public Health Law Research Program Strategic and Targeted Research Program Dissertation Grant Award, Robert Wood Johnson Foundation
2013-14	Health Policy Training Grant Award, National Institute of Mental Health
2013	Public Health Law Research Program Junior Scholar Travel Stipend Award, Robert Wood Johnson Foundation
2011-12	Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics Student Fellow, Harvard Law School
2010-12	Ph.D. Program in Health Policy Pre-Doctoral Training Fellowship Award, Harvard University
2009-10	New Alternatives Program Fellow, Ropes & Gray, LLP
2006	Fulbright U.S. Student Program Fellowship Grantee (Public Health – South Africa), United States Department of State
2006	Frank Knox Memorial Traveling Fellowship Award (Public Health – South Africa), Harvard University
2004	Summer Public Interest Funding Award (United Nations Criminal Tribunal for Rwanda), Harvard Law School
2004	Best Female Collegiate Soloist of the Year Contemporary A Cappella Recording Award, 2004, The Contemporary A Cappella Society
2002-03	Hart Leadership Fellow (Public Health Research – Tanzania), Duke University
2002	Graduation Magna Cum Laude, Duke University

PROFESSIONAL SERVICE AND MEMBERSHIP:

2020-	Executive Advisory Council Member, Economics, Sociology, and Statistics Department, RAND Corporation
2020-22	External Advisory Council Member, Arnold Ventures/Johns Hopkins Bloomberg School of Public Health study on the effects of opioid prescription limitation laws on prescribing and health
2019	External Reviewer, Foundation for Opioid Response Efforts (FORE) Grants on “Improving Access to Opioid Use Disorder Treatment and Recovery Services for Underserved Populations and Communities”
2019	Faculty Expert, University of Michigan Coursera/edX Massive Open Online Course, “Impacting the Opioid Crisis: Prevention, Education, and Practice for Non-Prescribing Providers”
2018	Paper Discussant, 13 th Annual Conference for Empirical Legal Studies, University of Michigan Law School, Ann Arbor, MI
2018	Faculty Mentor, Tarlise Townsend and Amanda Mauri, University of Michigan Injury Prevention Center Summer Fellowship Program
2018-19	Faculty Supervisor, JD/MPH Dual Degree Program, University of Michigan School of Public Health
2017-	Faculty Member, Public Health Law Watch: An Initiative of the George Consortium
2017-	Faculty Member, Internal Advisory Committee, Injury Prevention Center, University of Michigan
2017-19	Faculty Lead, Policy Committee, Injury Prevention Center, University of Michigan
2017	Faculty Expert, Coursera University of Michigan Teach-Out Course, “Solving the Opioid Crisis”
2016-19	Member Expert, Institute for Healthcare Policy and Innovation, University of Michigan

- 2016-19 Faculty Member, Center for Social Epidemiology and Population Health, University of Michigan
- 2016- Faculty Member Affiliate, Injury Prevention Center, University of Michigan
- 2016-19 Faculty Member, Mental Health Innovation, Services and Outcomes Program, University of Michigan
- 2016-19 Faculty Member, Health Management and Policy Research Committee, University of Michigan School of Public Health
- 2016-17 Faculty Member, Health Management and Policy Executive Master's Program Committee, University of Michigan School of Public Health
- 2016 Paper Discussant, 11th Annual Conference for Empirical Legal Studies, Duke University Law School, Durham, NC
- 2016 Content Adviser, Harvard X Course, "The Opioid Crisis in America"
- 2015- Peer Reviewer: *New England Journal of Medicine*, *JAMA*, *JAMA Internal Medicine*, *Health Affairs*, *Annals of Internal Medicine*, *International Journal of Drug Policy*, *Drug and Alcohol Dependence*, *Medical Care*, *BMJ*, *BMJ Open*, *American Journal of Preventive Medicine*, *American Journal of Public Health*, *Journal of Substance Abuse and Treatment*, *Pediatrics*, *Western Journal of Nursing*, *PLOS One*, *Mayo Clinic Proceedings*, *Journal of Law, Medicine & Ethics*, *The Lancet*, *Journal of General Internal Medicine*, *Yale Journal of Health Policy, Law, and Ethics*.
- 2014 Public Health Member, Expert Panel for Emergency Medicine Foundation study on identifying key characteristics for prescription drug monitoring programs for emergency department use

PROFESSIONAL SOCIETIES:

American Society of Law, Medicine & Ethics
 American Health Lawyers Association
 American Public Health Association
 AcademyHealth
 Society for Empirical Legal Studies

PROFESSIONAL AND RESEARCH EXPERIENCE:

- 2011-13 Research Assistant to Dr. Michelle Mello of Harvard School of Public Health on a Robert Wood Johnson Foundation study of provider "disclosure-and-offer" programs.
- 2009-10 Law Fellow, O'Neill Institute for National and Global Health Law, Georgetown University, Washington, DC
- 2006-09 Health Care Law Associate, Corporate Department, Ropes & Gray, LLP, Boston, MA and Washington, DC
- 2006 Legal Intern, Physicians for Human Rights, Cambridge, MA
- 2003-06 Managing Editor and Article Editor, Harvard Journal of Law and Gender, Harvard Law School, Cambridge, MA
- 2005 Summer Associate, Ropes & Gray, LLP, Boston, MA and Washington, DC
- 2004 Legal Intern, Office of the Prosecutor, United Nations International Criminal Tribunal for Rwanda, Arusha, Tanzania
- 2004 Research Assistant to Drs. Michelle Mello and Troyen Brennan of Harvard School of Public Health on a project related to advertising of junk foods and childhood obesity.
- 2002-03 Hart Research Leadership Fellow on a Duke University study led by Dr. Kathryn Whetten investigating the socio-cultural impact of HIV/AIDS in northern Tanzania.

- 1998-02 Music Director and Member, *Out of the Blue* a cappella singing group, Duke University, Durham, NC
- 2000-02 Business Director, Delta Delta Delta Sorority, Alpha Omicron Chapter, Duke University

MAJOR RESEARCH INTERESTS:

1. Empirical analysis of health laws and policies
2. Public health law and interventions
3. Behavioral health policy
4. Pharmaceutical policy
5. Injury prevention

RESEARCH SUPPORT:

CURRENT SUPPORT:

- 2020-23 Centers for Disease Control & Prevention, University of Michigan Injury Prevention Center Core Project (Haffajee, Bohnert – Multi-PIs)
The Association between Prescription Opioid Limitation Laws and Suicide Outcomes: Project examines the relationship between state prescription opioid limitation laws and fatal suicide outcomes in the U.S. population and nonfatal suicide outcomes (including attempts and ideation) in the commercially insured population.
(Contact Principal Investigator)
- 2019-21 Institute for Civil Justice, RAND Corporation (Haffajee, Kilmer, Helland – Multi-PIs)
Opioid Litigation in the U.S.: Evolution, Characteristics, and Outcomes: Project examines the trajectory of cases filed in the opioid litigation, to understand trends in geographic, party, claim, and other features of the cases over time. It also examines the association between opioid morbidity/mortality risk factors and opioid litigation characteristics.
(Multi-Principal Investigator)
- 2019-20 National Institute on Drug Abuse (P50 Supplement, Stein, Pacula – Multi-PIs)
The Opioid Policy, Technology, & Implementation Center for Research Excellence: Opioid Abatement Strategies: Administrative supplement identifies evidence-based and other promising emerging policies to prevent opioid misuse and addiction among adults and youth, and to mitigate harms to children of adults with opioid misuse and addiction. The resulting compendium will serve as a litigation resource for abatement strategies.
(Co-Investigator)
- 2019-22 National Institute of Mental Health (R01, Zivin – PI)
Relationship between Mental Health Coverage and Outcomes for Privately Insured Women with Perinatal Mood and Anxiety Disorders. Project assesses how changes in mental health coverage under the Mental Health Parity and Addition Equity Act and Patient Protection and Affordable Care Act affect delivery-related health outcomes, as well as utilization of and spending on mental health-related and overall health services.
(Co-Investigator)
- 2019-21 National Institute on Drug Abuse (R21, Heinze – PI)
Understanding Intergenerational Transmission of Drug Use in the Context of Cannabis Legalization: Study seeks to understand how the intergenerational transmission of the substance use is affected by Cannabis legalization in an at-risk sample of urban young adults and their children.
(Consultant)

2017-20 Centers for Disease Control & Prevention, National Center for Injury Control and Prevention (#1U01CE002780-01) (Bohnert, Larochelle – Multi-PIs)
Heroin Use and Overdose Following Changes to Individual-Level Opioid Prescribing: Project examines to what extent patients tapered from high dosages of prescription opioids experience heroin-related overdoses using secondary commercial claims data and qualitative interviews.
 (Co-Investigator)

PAST SUPPORT:

- 2018-19 Health Resources and Services Administration (#U81HP293000400, Beck – PI)
Behavioral Health Workforce Research Center: Center conducts national studies on behavioral health workforce. Led projects on workforce provider roles/opportunities in treating opioid use disorder.
 (Co-Investigator)
- 2017-19 National Center for Advancing Translational Sciences of the National Institutes of Health, Michigan Institute for Clinical and Health Research (#KL2TR002241) (Haffajee – PI)
Differential Prescription Drug Monitoring Program Effects across Specialties and Patient Populations: Career development award allowed study of prescription drug monitoring and other opioid policy impacts across patient and prescriber populations using secondary data analysis.
 (Principal Investigator)
- 2018-19 Michigan Department of Health and Human Services, Prescription Drug Overdose Prevention Initiative
Prescription Drug Monitoring Program and Opioid Policy Evaluation: Project examines, using administrative claims data, opioid prescribing measures in Michigan, relative to upgrades to the Michigan Automated Prescription System (MAPS). Consult regarding state evaluations of naloxone distribution laws and other opioid policies.
 (Consultant)
- 2018-19 Centers for Disease Control & Prevention, University of Michigan Injury Center Core Project (#CDC 3R49CE002099-05S1) (Bohnert, Maust – Multi-PIs)
The Effect of a Prescription Drug Coverage Policy on Risk of Falls and Overdose in Older Adults: Project examines the effect of Medicare coverage policy changes for benzodiazepines on the rate of fall-related injuries and unintentional overdose among elderly individuals in Medicare advantage plans, including those prescribed opioid analgesics.
 (Co-Investigator)
- 2018-19 Laura and John Arnold Foundation (Frank – PI)
Generic Drug Policy and Opioid Disorder Treatment: Project investigates naloxone and buprenorphine pricing trends and generic drug policy to elucidate market and regulatory factors that affect the availability of opioid disorder treatments.
 (Consultant)
- 2017-18 Walter J. McNerney Award, Department of Health Management and Policy, University of Michigan School of Public Health (Haffajee – PI)
Opioid Prescriber Responses to Opioid Prescribing Prevention Policies: Project surveys a nationally representative sample of physicians across four high-volume opioid prescriber specialties to understand their knowledge and perception of, and behavior changes in response to, key national-, state-, and provider-level opioid prescribing prevention policies.
 (Principal Investigator)
- 2017-18 Centers for Disease Control & Prevention, National Center for Injury Control and Prevention (CDC 3R49CE002099-05S1) (Cunningham – PI)
University of Michigan Injury Prevention Center: The mission of the University of Michigan Injury Prevention Center is to conduct high-quality injury research and training, to translate scientific discoveries into practice and policy, and to reduce injuries, violence and related disabilities.
 (Faculty Investigator)

- 2016-18 Department of Population Medicine Faculty Grant, Harvard Medical School and Harvard Pilgrim Health Care Institute (Wagner – PI)
Addressing Payers' Challenges in Managing Novel Cancer Therapy Coverage
(Co-Investigator/Consultant)
- 2016-17 Centers for Disease Control & Prevention, Injury Control Prevention Centers (ICPC) Thematic Network, University of Michigan Injury Prevention Center
Addressing Opioid Misuse, Abuse, and Overdose: Project coordinates work across four CDC-funded ICPCs and disseminates evidence-based recommendations for addressing the opioid epidemic.
(Co-Investigator)
- 2015-16 Graduate School of Arts and Sciences, Harvard University (Dissertation Completion Grant)
Evaluating Legal Interventions Designed to Improve Behavioral Health Outcomes
- 2014-15 Department of Population Medicine Thomas O. Pyle Fellowship Grant, Harvard Medical School and Harvard Pilgrim Health Care Institute
Impact of Prescription Drug Monitoring Programs on Prescribing and Abuse of Prescription Drugs
- 2013-14 Department of Population Medicine Thomas O. Pyle Fellowship Grant, Harvard Medical School and Harvard Pilgrim Health Care Institute
Impact of Mental Health Parity Laws on Mental Health Treatment and Outcomes
- 2013-14 Public Health Law Research Program Strategic and Targeted Research Program, Robert Wood Johnson Foundation (Dissertation Grant)
Impact of Mental Health Parity Laws on Mental Health Treatment and Outcomes
- 2013-14 National Institute of Mental Health (Health Policy Training Grant)
Evaluating Legal Interventions Designed to Improve Behavioral Health Outcomes
- 2012-13 Department of Population Medicine Pharmaceutical Policy Research Fellowship Grant, Harvard Medical School and Harvard Pilgrim Health Care Institute
Impacts of Mental Health Parity Laws Designed to Increase Access to Care and Treatment

TEACHING EXPERIENCE:

- 2017-19 *Law and Public Health*. Health Management and Policy Department, University of Michigan School of Public Health & University of Michigan Law School. Lead Instructor. Designed and taught course curriculum.
- 2017-18 *Calling Bullshit*. Health Management and Policy Department, University of Michigan School of Public Health. Co-Instructor. Co-taught with Professors Scott Greer, Edward Norton, and Jeffrey McCullough seminar on identifying, addressing, and considering the ethical implications of “bullshit” in health services and health policy research.
- 2017 *Program Evaluation*. Health Management and Policy Department, University of Michigan School of Public Health. Lead Instructor. Coordinated and co-taught with Professors Daniel Eisenberg and Neil Mehta seminar on methods for program evaluation in public health.
- 2013-14 *Core Course in Health Policy*. Graduate School of Arts and Sciences, Harvard University. Teaching Fellow to Professors Joseph Newhouse and Alan Zaslavsky.
- 2012 *Public Health Law*. Harvard School of Public Health. Teaching Assistant to Professor Michelle Mello.
- 2011 *Empirical and Mathematical Reasoning 20: The Business and Politics of Health*. Faculty of Arts and Sciences, Harvard University. Head Teaching Fellow to Professor David Cutler.
- 2010 *International Women's Human Rights Clinic*. Georgetown University Law Center. Co-Instructor (included a clinical trip to Namibia).

- 2009-10 *International Health Regulations*. World Health Organization. Head Instructor and Course Coordinator (on behalf of Georgetown University Law Center) for legal components of the International Health Regulations.
- 2006 *Making Rights Real: The Ghana Project*. Harvard Law School. Clinical Teaching Assistant to Professor Lucie White (included a clinical trip to Ghana).
- 2001 *Computer Science 4: Introduction to Programming*. Duke University. Teaching Assistant to Professor Dietolf Ramm.
- 1999-2000 *SAT Math*. The Princeton Review. Course Instructor and Tutor.

DOCTORAL STUDENT ADVISING:

- Charley Willison, MPH, MA – PhD in Health Services, Organization and Policy, University of Michigan (2019)
- Tarlise Townsend, MPH – PhD in Health Services, Organization and Policy & PhD in Sociology, University of Michigan (2020)
- Amanda Mauri, MPH – PhD in Health Services, Organization and Policy, University of Michigan (anticipated 2022)
- Cecelia French, MPH – PhD in Human Behavior and Health Education, University of Michigan (anticipated 2022)

BIBLIOGRAPHY:

ARTICLES:

- Admon LK, Dalton VK, Kolenic GE, Ettner SL, Tilea A, **Haffajee RL**, Brownlee RM, Zochowski MK, Tabb KM, Muzik M, Zivin K. Trends in suicidality 1 year before and after birth among commercially insured childbearing individuals in the United States, 2006-2017. *JAMA Psych Online* First Nov. 18, 2020, doi:10.1001/jamapsychiatry.2020.3550.
- Haffajee RL**, Andraka-Christou B, Dormond M, Cupito A, Buche J. A mixed-method comparison of physician-reported knowledge about and barriers to treatment with medications for opioid use disorder. *Substance Abuse Treatment, Prevention, & Policy* 2020;15:69.
- Leopold C, **Haffajee RL**, Lu CY, Wagner AK. The complex cancer care coverage environment – what is the role of legislation? A case study from Massachusetts. *J L Med Ethics* 2020;48(3):538-551.
- Haffajee RL**. The public health value of opioid litigation. *J L Med Ethics* 2020;48(2):279-292. PMID: PMC7481928
- Dora-Laskey AD, Goldstick JE, Arterberry BJ, Roberts SJ, **Haffajee RL**, Bohnert ASB, Cunningham RC, Carter PM. Prevalence and predictors of driving after prescription opioid use in an adult ED sample. *West J Emerg Med* 2020;21(4):831-40. PMID: PMC7390550
- Lagisetty PA, Zhang K, **Haffajee RL**, Lin LA, Goldstick J, Brownlee R, Bohnert ASB, Larochelle MR. Opioid prescribing history prior to heroin overdose among commercially insured adults. *Drug & Alc Depend* 2020;212:10806. PMID: 32428788
- Haffajee RL**, Mello MM. Thinking globally, acting locally – the U.S. Response to Covid-19. *N Eng J Med* 2020 Apr. 2. doi: 10.1056/NEJMp2006740. PMID: 32240580
- Alexander GC, Stoller KB, **Haffajee RL**, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. *Ann Int Med* 2020 Apr. 2. doi: 10.7326/M20-1141. PMID: PMC7138407.

8. Maust DT, Lin LA, Goldstick JE, **Haffajee RL**, Brownlee R, Bohnert ASB. Association of Medicare Part D benzodiazepine coverage expansion with changes in fall-related injuries and overdoses among Medicare Advantage beneficiaries. *JAMA Netw Open* 2020;3(4):e202051. PMID: PMC7125434.
9. **Haffajee RL**, Cherney S, Smart R. Legal requirements and recommendations to prescribe naloxone. *Drug & Alc Depend* 2020;209:107896. PMID: PMC7127952.
10. **Haffajee RL**, Frank RG. Abuses of FDA regulatory procedures — the case of Suboxone. *N Eng J Med* 2020;382(6):496-498. PMID: 31914238
11. **Haffajee RL**, Abrams MR. Settling the score: maximizing the public health impact of opioid litigation. *Ohio St Law J* 2020; 80(4):701-740 (ranked 41/948 U.S. law journals).
12. **Haffajee RL**, Frank RG. Generic drug policy and Suboxone[®] to treat opioid use disorder. *J L Med Ethics* 2019;47(S4):43-53. PMID: 31955697
13. Mauri AM, Townsend T, **Haffajee RL**. The association of state opioid misuse prevention policies with patient- and provider-related outcomes: a scoping review. *Millbank Q* 2019;98(1):57-105. PMID: PMC7077777
14. Agarwal S, Bryan JD, Hu HM, Lee JS, Chua KP, **Haffajee RL**, Brummett CM, Englesbe MJ, Waljee JF. Association of state opioid duration limits with postoperative opioid prescribing. *JAMA Netw Open* 2019;2(12):e1918361. PMID: PMC6991309
15. **Haffajee RL**. Prescription drug monitoring programs: friend or folly in addressing the opioid-overdose crisis? *N Eng J Med* 2019;381:699-701. PMID: 31433916; PMID: PMC7486903
16. Lagisetty PA, Lin LA, Ganoczy D, **Haffajee RL**, Bohnert ASB. Opioid prescribing after opioid-related inpatient hospitalizations by diagnosis: a cohort study. *Med Care* 2019;57(10):815-821. PMID: PMC6742521
17. **Haffajee RL**, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of U.S. counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. *JAMA Netw Open* 2019;2(6):e196373. PMID: PMC6604101
18. **Haffajee RL**, Mello MM, Zhang F, Busch AB, Zaslavsky AM, Wharam JF. Association of federal mental health parity legislation with health care use and spending among high utilizers of services. *Med Care* 2019;57(4):245-255. PMID: PMC6423539
19. **Haffajee RL**, French CA. Provider perceptions of system-level opioid prescribing and addiction treatment policies. *Curr Opin Psychol* 2019;30:65-73. PMID: 30856591; PMID: PMC7482312
20. Chua KP, Brummett CM, Conti R, **Haffajee RL**, Prosser L, Bohnert ASB. Assessment of prescriber and pharmacy shopping among the family members of patients prescribed opioids. *JAMA Netw Open* 2019;2(5):e193673. PMID: PMC6512276
21. Boehnke KF, Gangopadhyay S, Clauw DJ, **Haffajee RL**. Qualifying conditions of medical cannabis license holders in the United States. *Health Aff* 2019;38(2):295-302. PMID: PMC6398594
22. Yang TY, Weintraub E, **Haffajee RL**. Telemedicine's role in addressing the opioid crisis. *Mayo Clin Proc.* 2018;93(9):1177-1180. PMID: PMC6330237

23. Kennedy-Hendricks A, Epstein AJ, Stuart EA, **Haffajee RL**, McGinty EE, Busch AB, Huskamp H, Barry CL. Federal parity and spending for mental illness. *Pediatrics* 2018;142(2):e20172618. PMID: PMC6317554
24. **Haffajee RL**, MacCoun RJ, Mello MM. Behind schedule—reconciling federal and state marijuana policy. *N Engl J Med* 2018;379(6):501-504. PMID: 29996065
25. **Haffajee RL**, Mello MM, Zhang F, Zaslavsky AM, Larochelle MR, Wharam JF. Four states with robust prescription drug monitoring programs reduced opioid dosages. *Health Aff* 2018;37(6):964-74. PMID: PMC6298032
26. **Haffajee RL**, Bohnert ASB, Lagisetty PA. Policy pathways to address workforce barriers to buprenorphine treatment. *Am J Prev Med* 2018;54(6):S230-S242. PMID: PMC6330240
27. **Haffajee RL**, Frank RG. Making the opioid public health emergency effective. *JAMA Psych* 2018;75(8):767-768. PMID: PMC6378105
28. **Haffajee RL**, Mello MM. Drug companies' liability for the opioid epidemic. *N Engl J Med* 2017;377(24):2301-2305. PMID: 29236640; PMID: PMC7479783
29. Yang TY, Larochelle MR, **Haffajee RL**. Managing increasing liability risks related to opioid prescribing. *Am J Med* 2017;130(3):249-50. PMID: 27644150
30. Yang TY, **Haffajee RL**. Murder liability for prescribing opioids: a way forward? *Mayo Clin Proc* 2016; 91(10):1331-35. PMID: 27502463; PMID: PMC7490802
31. **Haffajee RL**. Preventing opioid misuse with prescription drug monitoring programs: a framework for evaluating the success of state public health laws. *Hastings Law J* 2016; 67(6):1621-1694 (ranked 34/948 U.S. law journals).
32. **Haffajee RL**, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. *JAMA* 2015;313(9):891-892. PMID: PMC4465450
33. **Haffajee RL**, Parmet WE, Mello MM. What is a public health “emergency”? *N Engl J Med* 2014;371(11):986-988. PMID: 25207765
34. **Haffajee RL**, Bloche GM. The FCTC and the psychology of tobacco control. *Asian J WTO Int'l Health Law & Pol'y* 2010;5(1): 87-113 (ranked 720/1537 U.S. & international law journals).
35. **Haffajee RL**. The potential use of joint criminal enterprise theory in prosecuting crimes of rape and sexual violence at the ICTR. *Harvard J Law & Gender* 2006;29(1):201-221 (ranked 85/948 U.S. law journals).
36. **Haffajee RL**. Genetic discrimination legislation in Massachusetts. *GeneWatch* 2000;13(5/6).
37. **Haffajee RL**. Medicare prescription drug benefits tug of war. *Capital Eye* 2001;8:5.

UNDER REVIEW:

1. Townsend T, Cerda M, Bohnert ASB, Lagisetty PA, **Haffajee RL**. Effects of the CDC Guideline for opioid prescribing for chronic pain: a national, longitudinal analysis.
2. **Haffajee RL**, Kilmer B, Helland E. Government opioid litigation: the scope of liability.

3. Cantor J, Dick AW, **Haffajee RL**, Pera MF, Bravata DM, Stein BD, Whaley C. Use of medications for opioid use disorder during the initial phase of the COVID-19 pandemic.
4. Bohnert ASB, Lin LA, Lagisetty PA, **Haffajee RL**, Zhang K, Brownlee R, Goldstick JE, Laroche MR. Association of opioid and benzodiazepine prescriptions with risk of treated suicide attempts: A national cohort study.
5. Andraka-Christou B, Page C, Buche J, Schoebel V, **Haffajee RL**. Knowledge of and barriers to treatment with medications for opioid use disorder among nurse practitioners and physician assistants: a national survey.

OTHER:

1. Garabedian LF, **Haffajee RL**. Schools need to assume kids can get and spread COVID, and operate safely for all ages. USA Today. Aug. 28, 2020. Available at: <https://www.usatoday.com/story/opinion/2020/08/28/coronavirus-child-studies-inconclusive-schools-precautions-column/3434655001/>
2. **Haffajee RL**, Lin LA, Page C, et al. Access to treatment for opioid use disorder: a survey of addiction medicine physicians on telemedicine and medication-assisted treatment. Behavioral Health Workforce Research Center, University of Michigan. Dec. 2019. Available at: <http://www.behavioralhealthworkforce.org/project/understanding-telemedicines-role-in-providing-medication-assisted-treatment-to-treat-opioid-use-disorders-barriers-facilitators-and-areas-of-need/>
3. Mauri A, **Haffajee RL**. Beyond bans: how cannabis policy reform can reduce vaping-related illnesses. Health Aff Blog, Mar. 26, 2020. Available at: <https://www.healthaffairs.org/doi/10.1377/hblog20200323.90505/full/>
4. **Haffajee RL**, Stein B. Spending the opioid settlement most effectively. Pitt Gazette. Dec. 19, 2019. Available at: <https://www.post-gazette.com/opinion/Op-Ed/2019/12/19/Rebecca-Haffajee-Bradley-Stein-Spending-the-opioid-settlement-most-effectively/stories/201912190053>
5. Harbraugh C, Malani P, **Haffajee RL**, Waljee JF. The culture of pain: perceptions of opioid-related policy among U.S. older adults. Health Aff Blog, Apr. 17, 2019. Available at: <https://www.healthaffairs.org/doi/10.1377/hblog20190415.123669/full/>.
6. Boehnke KF, **Haffajee RL**. Medical Cannabis and Pain: The Author's Reply. Health Aff 2019;38(4):694.
7. Boehnke KF, Clauw DJ, **Haffajee RL**. Letter to the editor: on chronic pain as a qualifying condition for medical cannabis licenses. Health Aff 2019;38(5):874.
8. Frank RG, **Haffajee RL**. Generic drug policy and opioid use disorder treatment. Laura and John Arnold Foundation: White Paper, Jan. 2019.
9. Frank RG, **Haffajee RL**. The Trump administration's actions to solve the opioids public health crisis: a reply. JAMA Psych. 2019;76(1):101-102.
10. Atterman J, Dormand J, Schreiber J, **Haffajee RL**, et al. Behavioral health workforce challenges related to medication assisted treatment. Behavioral Health Workforce Research Center, University of Michigan. Jan. 2018. Available at: http://www.behavioralhealthworkforce.org/wp-content/uploads/2018/04/Y2FA3P2_MAT-Full-Report.pdf.

11. **Haffajee RL**. Will public health litigation help to solve the opioid crisis? Public Health Law Watch Blog. Dec. 21, 2017. Available at: <https://www.publichealthlawwatch.org/blog/2017/12/22/will-public-health-litigation-help-to-solve-the-opioid-crisis?rq=haffajee>.
12. **Haffajee RL**, Liber AC, Warner KE. A safer way to legalize marijuana. Health Affairs Blog, Sept. 8, 2017. Available at: <https://www.healthaffairs.org/doi/10.1377/hblog20170908.061869/full/>.
13. Carter P, Abir M, Bohnert ASB, Cunningham RC, Dora-Laskey A, **Haffajee RL**, Martin J, Walton M. The prescription opioid epidemic in Michigan: evidence, expertise, and recommendations for action. University of Michigan Injury Center. Sept. 2017.
14. **Haffajee RL**. Fight the urge to criminalize opioid addiction behaviors. Health Affairs Blog, March 9, 2016. Available at: <http://healthaffairs.org/blog/2016/03/09/fight-the-urge-to-criminalize-opioid-addiction-behaviors/>.
15. **Haffajee RL**. Widespread use of prescription drug monitoring programs to reduce opioid abuse and overdoses. Bill of Health Blog, Harvard Law School / Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics. Mar. 9, 2015. Available at: <http://blogs.harvard.edu/billofhealth/2015/03/09/widespread-use-of-prescription-drug-monitoring-programs-to-reduce-opioid-abuse-and-overdoses/>.
16. **Haffajee RL**. What is (or isn't) a public health "emergency"? Bill of Health Blog, Harvard Law School Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics. Sept. 12, 2014. Available at: <http://blogs.harvard.edu/billofhealth/2014/09/12/what-is-or-isnt-a-public-health-emergency/>.
17. **Haffajee RL**. Soda industry sues to block NYC ban on sugar-sweetened beverage sales. Bill of Health Blog, Harvard Law School / Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics. Oct. 15, 2012. Available at: <http://blogs.harvard.edu/billofhealth/2012/10/15/soda-industry-sues-to-block-nyc-ban-on-soda-sales/>.
18. **Haffajee RL**. What do we know about obesity and its prevention in the U.S. Bill of Health Blog, Harvard Law School / Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics. Oct. 5, 2012. Available at: <http://blogs.harvard.edu/billofhealth/2012/10/05/what-do-we-know-about-obesity-and-its-prevention-in-the-u-s/>.
19. **Haffajee RL**. MA health reform and medical debt – getting the facts straight. Bill of Health Blog, Harvard Law School / Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics. Sept. 12, 2012. Available at: <http://blogs.harvard.edu/billofhealth/2012/09/12/ma-health-reform-and-medical-debt-getting-the-facts-straight/>.

UNDER PREPARATION:

1. **Haffajee RL**, Goldstick JE, Bohnert ASB, Myers M, Boehnke K. Association between county-level medical cannabis registrations and opioid-related outcomes.
2. Andraka-Christou B, Bouskill K, **Haffajee RL**, Randall-Kosich O, Golan M, Totarum R, Stein B. COVID-19 related policy changes to SUD treatment: content analysis of single state agency websites.
3. **Haffajee RL**, Lin LA, Buche J, Page C. Telemedicine to treat opioid use disorder: a survey of addiction treatment specialists.
4. **Haffajee RL**, Bohnert ASB, Lin LA, Lagisetty PA, Zhang K, Brownlee R, Goldstick JE, Larochelle MR. Association of opioid and benzodiazepine prescriptions with risk of overdose: A national cohort study.

5. **Haffajee RL**, Townsend T, Mello MM, Larochelle MR, Cunningham RC, Goldstick JE, Myers MG, Bohnert ASB. Disparate effects of state opioid prescribing regulations on patient demographic subgroups.
6. **Haffajee RL**, Faherty L, Zivin K. Supporting, not punishing, women with substance use disorder in pregnancy.

SELECTED MEDIA:

1. “States of emergency,” Work cited by Nicholas Bagley for *The Incidental Economist*. Sept. 12, 2014. Available at: <https://theincidentaleconomist.com/wordpress/states-of-emergency/>.
2. “Rise in prescription drug overdose deaths is slowing. Do monitoring programs deserve credit?” Interview for *Sound Medicine Radio*. Feb. 27, 2015. Available at: <http://soundmedicine.org/post/rise-prescription-drug-overdose-deaths-slowing-do-monitoring-programs-deserve-credit>.
3. “Tackling prescription drug abuse,” Interview with Brian Owens for *The Pharmaceutical Journal*. June 11, 2015. Available at: <https://www.pharmaceutical-journal.com/news-and-analysis/features/tackling-prescription-drug-abuse/20068685.article>.
4. “Prescription tracking tackles misuse of opioids and other drugs – but results vary,” Interview with Kara Gavin for *Michigan Medicine*. July 20, 2017. Available at: <http://ihpi.umich.edu/news/prescription-tracking-tackles-misuse-opioids-other-drugs-%E2%80%94-results-vary>.
5. “Forced sterilization won’t fix the drug crisis,” Interview with S.E. Smith for *Rewire*. Aug. 3, 2017. Available at: <https://rewire.news/article/2017/08/03/forced-sterilization-wont-fix-drug-crisis/>.
6. “What would happen if Trump declared the opioid epidemic a national emergency,” Interview with Francie Diep for *Pacific Standard*. Aug. 4, 2017. Available at: <https://psmag.com/news/what-would-happen-if-trump-declared-opioid-epidemic-national-emergency>.
7. “Trump is declaring opioid addiction a national emergency after all,” Interview with Francie Diep for *Pacific Standard*. Aug. 10, 2017. Available at: <https://psmag.com/news/trump-declares-opioid-addiction-a-national-emergency>.
8. “Legalizing marijuana should not include smoked form, say U-M experts,” Interview with/and article referenced by Laurel Thomas for *Michigan News, Association of Schools and Programs for Public Health*. Sept. 8, 2017. Available at: <https://news.umich.edu/legalizing-marijuana-should-not-include-smoked-form-say-u-m-experts/>.
9. “What do Harvey and Irma mean for America’s opioid emergency,” Interview with Francie Diep for *Pacific Standard*. Sep. 13, 2017. Available at: <https://psmag.com/social-justice/what-do-harvey-and-irma-mean-for-americas-opioid-emergency>.
10. “Trump says he's going to declare the opioid crisis a national emergency. Here's what that means,” Interview with Jeffrey Cook for *ABC News*. Oct. 23, 2017. Available at: <http://abcnews.go.com/Politics/trump-declare-opioid-crisis-national-emergency-means/story?id=50618305>.
11. “U.S. national emergency declaration for the opioid crisis,” Interview with David Whitty for *BBC World Service Radio*. Oct. 25, 2017.

12. "Trump's emergency declaration on opioid crisis will require further funding," Interview with Vivian Salama for *NBC News*. Oct. 26, 2017. Available at: <https://www.nbcnews.com/storyline/americas-heroin-epidemic/trump-s-emergency-declaration-opioid-crisis-will-require-further-funding-n814416>.
13. "Tackling the opioid epidemic: Using alternative therapies and new technologies to curb a national crisis," Interview with Andrea LaFerle for *Findings Magazine*. Oct. 26, 2017. Available at: <https://sph.umich.edu/news/home-releases/tackling-opioids-102517.html>.
14. "Opioids," Interview with John Otrompke for *Burroughs Healthcare Consulting Network*. Oct. 27, 2017. Available at: <https://burroughshealthcare.com/2017/10/27/opioid-epidemic-a-multi-factorial-solution-including-drug-price-negotiation-and-interstate-prescription-monitoring/>.
15. "Teach-out focusing on opioid epidemic starts Dec. 4," Interview with Laurel Thomas for *The University Record*. Nov. 22, 2017. Available at: <http://record.umich.edu/articles/u-m-teach-out-focusing-opioid-epidemic-starts-dec-4>.
16. "Opioid epidemic weighing heavy on local governments: new strategies planned to combat drugs," Quoted by Matthew Smith for *WXYZ Detroit*. Nov. 29, 2017. Available at: <https://www.wxyz.com/news/opioid-epidemic-weighing-heavy-on-local-governments>.
17. "Interview with Dr. Rebecca Haffajee on the growing number of lawsuits against opioid manufacturers and distributors," *New England Journal of Medicine*. Dec. 14, 2017. Available at: http://www.nejm.org/action/showMediaPlayer?doi=10.1056%2FNEJMp1710756&aid=NEJMp1710756_attach_1&area=.
18. "Drug overdose deaths continue to soar," Article referenced by Steve Sternberg for *U.S. News & World Reports*. Dec. 15, 2017. Available at: <https://www.usnews.com/news/national-news/articles/2017-12-15/drug-overdose-deaths-continue-to-soar>.
19. "Going after opioid manufacturers, distributors in court may help crisis," Interview with Laurel Thomas for *The University Record, Association of American Universities*. Dec. 13-18, 2017. Available at: <http://record.umich.edu/articles/going-after-opioid-manufacturers-distributors-court-may-help-crisis>.
20. "To fight the opioid epidemic, take drug makers to court?" Interview with Laurel Thomas for *Futurity*. Dec. 19, 2018. Available at: <https://www.futurity.org/suing-opioid-manufacturers-1635662/>.
21. "In the fight against the opioid epidemic, lawsuits could be a useful tool," Interview with April Van Buren for *Michigan Radio, NPR News Station*. Dec. 18, 2017. Available at: <http://michiganradio.org/post/fight-against-opioid-epidemic-lawsuits-could-be-useful-tool>.
22. "Lansing sues drug companies over opioid epidemic," Interview with Sarah Lehr for *Lansing State Journal*. Dec. 19, 2017. Available at: <https://www.lansingstatejournal.com/story/news/2017/12/19/lansing-sues-drug-companies-over-opioid-epidemic/964003001/>.
23. "New legal approaches may compel drug companies to pay for opioid crisis," Article referenced by Steve Dubb for *Nonprofit Quarterly*. Dec. 20, 2018. Available at: <https://nonprofitquarterly.org/2017/12/20/new-legal-approaches-may-compel-drug-companies-pay-opioid-crisis/>.
24. "Ron Johnson uses altered data to blame opioid crisis on Medicaid," Interview with Amanda Gomez for *Think Progress*. Jan. 17, 2018. Available at: <https://thinkprogress.org/misleading-data-opioid-crisis-medicaid-e34e3f354b8e/>.

25. "Opioid emergency declarations offer short-term benefit on a 'slippery slope,'" Interview with Ryan McDonald for *Healio*. Jan. 19, 2018. Available at: <https://www.healio.com/hematology-oncology/practice-management/news/online/%7B4463e79d-f79e-4a1b-809b-f0b06cebc500%7D/opioid-emergency-declarations-offer-short-term-benefit-on-a-slippery-slope>.
26. "The Sackler family made billions from OxyContin. Why do top US colleges take money tainted by the opioid crisis?" Article referenced by Steve Dubb and Amy Costello in *The Guardian*. Jan. 27, 2018. Available at: <https://www.theguardian.com/us-news/2018/jan/27/universities-sackler-family-purdue-pharma-oxycontin-opioids>.
27. "Baltimore sues opioid manufacturers, distributors and a local doctor's office over pain pills," Interview with Ian Duncan for *The Baltimore Sun*. Jan. 31, 2018. Available at: <http://www.baltimoresun.com/news/maryland/baltimore-city/bs-md-ci-city-opioid-suit-20180131-story.html>.
28. "How effective are opioid lawsuits?" Interview with Reuben Jones for *Spectrum News*. Feb. 1, 2018. Available at: <http://spectrumlocalnews.com/nc/charlotte/news/2018/02/01/opioid-crisis-lawsuits--are-they-effective->.
29. "Council seeks steps vs. opioid makers and Holyoke Mayor Alex Morse considering 'taking action,'" Article referenced by Mike Plaisance in *MLive*. Feb. 11, 2018. Available at: http://www.masslive.com/news/index.ssf/2018/02/council_seeks_action_vs_opioid.html.
30. "Purdue Pharma cease promotion of OxyContin to doctors," Interview with Andy Polhamus for *Healio*. Feb. 13, 2018. Available at: <https://www.healio.com/hematology-oncology/practice-management/news/online/%7Bf449c490-270b-4d7f-961b-7d42f2334ed1%7D/purdue-pharma-ceases-promotion-of-oxycontin-to-doctors>.
31. "A south Texas county drags PBMs into nationwide lawsuit over opioids," Interview with Casey Ross for *STAT*. Feb. 26, 2018. Available at: https://www.statnews.com/2018/02/26/texas-pbm-opioid-lawsuit/?utm_source=STAT+Newsletters&utm_campaign=53fc2df257-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-53fc2df257-150070213.
32. "Pharmacy benefits managers in crosshairs of latest opioid lawsuit," Quoted by Marlene Satter for *Benefitspro*. Feb. 26, 2018. Available at: <https://www.benefitspro.com/2018/02/26/pharmacy-benefits-managers-in-crosshairs-of-latest/>.
33. "Justice Department to join wave of state, city lawsuits against opioid makers, Sessions says," Interview with Jon Schuppe for *NBC News*. Feb. 27, 2018. Available at: <https://www.nbcnews.com/news/us-news/justice-department-join-wave-state-lawsuits-against-opioid-makers-sessions-n851721>.
34. "Opioid lawsuit places blame of pharmacy benefit managers," Quoted by Laurie Toich for *The American Journal of Pharmacy Benefits*. Mar. 1, 2018. Available at: <https://www.ajpb.com/news/opioid-lawsuit-places-blame-on-pharmacy-benefit-managers>.
35. "From pills to pot: The future of medical marijuana in Ohio," Interview with Amanda Fay for *WTOL 11*. Mar. 9, 2018. Available at: <http://www.wtol.com/story/37686440/from-pills-to-pot-the-future-of-medical-marijuana-in-ohio>.
36. "Q&A: Holding drugmakers accountable for the opioid crisis," Interview with Associated Press published by *The New York Times*, *The Washington Post*, *ABC News*, *NBC News*, *Yahoo*, *San Francisco Chronicle*.

- March 18, 2018. Available at: <https://www.nytimes.com/aponline/2018/03/18/business/ap-us-insider-qa-opioid-lawsuits.html>.
37. "Opioid solutions promotes collaborative approach to the epidemic," Work referenced by Alex Piazza for *The University Record*. Apr. 18, 2018. Available at: <http://record.umich.edu/articles/opioid-solutions-promotes-collaborative-approach-epidemic>.
 38. "Opioid epidemic: more funding needed," Interview with/article referenced by Nardy Baeza Bickel for *Michigan News, Medical Xpress, Association of Schools and Programs of Public Health*. Apr. 26, 2018. Available at: <http://ns.umich.edu/new/releases/25603-opioid-epidemic-more-funding-needed>; <https://medicalxpress.com/news/2018-04-resources-combat-opioid-epidemic.html>.
 39. "Experts suggest Trump declare opioid epidemic a 'national emergency'," Work referenced by *Healio Psychiatric Annals*. May 1, 2018. Available at: <https://www.healio.com/psychiatry/addiction/news/online/%7Bf85ce7ef-874c-426e-87ee-9447023ff831%7D/experts-suggest-trump-declare-opioid-epidemic-a-national-emergency>.
 40. "Lawmakers to grill drug wholesalers over opioid epidemic," Interviewed by Dan Gorenstein for *Marketplace (Public Radio Program)*. May 8, 2018. Available at: <https://www.marketplace.org/2018/05/08/health-care/lawmakers-grill-drug-wholesalers-over-opioid-epidemic>.
 41. "More funding needed to quash the opioid crisis in the US," Work cited by Scott Repholz for *Lifenism*. May 12, 2018. Available at: <http://lifenism.com/2018/05/12/more-funding-is-needed-to-quash-the-opioid-crisis-in-the-us/>.
 42. "Michigan: policy considerations for addressing opioid crisis workforce needs and overcoming barriers to provision of buprenorphine," Work cited by *Association of Schools & Programs of Public Health*. May 15, 2018. Available at: <https://www.aspph.org/michigan-policy-considerations-for-addressing-opioid-crisis-workforce-needs-and-overcoming-barriers-to-provision-of-buprenorphine/>.
 43. "Behavioral health workforce faces critical challenges in meeting population needs," Interviewed by *American Journal of Preventive Medicine* regarding press release for Special Supplement article for *EurekaAlert, Medical Xpress, AlphaGalileo, Science Daily*. May 17, 2018. Available at: https://www.eurekaalert.org/pub_releases/2018-05/e-bhw051518.php.
 44. "Hold them to account: Pittsburgh joins a broad suit against drug industry," Work referenced by The Editorial Board for *Pittsburgh Post-Gazette*. May 17, 2018. Available at: <http://www.post-gazette.com/opinion/editorials/2018/05/17/Hold-them-to-account-Pittsburgh-joins-a-broad-suit-against-drug-industry/stories/201805170046>.
 45. "Stein right to go after drug firms as a major part of opioid abuse plague." Work cited by the Capitol Broadcasting Company Editorial team. May 25, 2018. Available at: <https://www.wral.com/editorial-stein-is-right-to-go-after-drug-firms-as-a-major-part-of-the-opioid-abuse-plague/17579067/>.
 46. "Bolingbrook backs national opioid lawsuit," Work cited by Grace Tucker for *Bugle News*. June 7, 2018. Available at: <https://buglenewspapers.com/bolingbrook-backs-national-opioid-lawsuit>.
 47. "County moves on opioid suit," Work references by Don Reid for *Coldwater Daily Reporter*. June 14, 2018. Available at: <http://www.thedailyreporter.com/news/20180614/county-moves-on-opioid-suit>.

48. “All state opioid monitoring programs are not created equal,” Interviewed by Nardy Baeza-Bickel for *Michigan News, Medical Xpress, Association of Schools and Programs of Public Health*. June 7, 2018. Available at: <https://medicalxpress.com/news/2018-06-state-opioid-equal.html>.
49. “New study finds robust drug monitoring programs reduce over prescription,” Interviewed by Ben Thorp for WCMU Public Radio. June 7, 2018. Available at: <http://radio.wcmu.org/post/new-study-finds-robust-drug-monitoring-programs-reduce-over-prescription>.
50. “4 U.S. states beat all others at cutting opioid dosages,” Interviewed by Nardy Baeza-Bickel for *Michigan News, Futurity*. June 18, 2018. Available at: <https://www.futurity.org/opioids-state-programs-cutting-dosage-1787402/>.
51. “These 4 states saw the biggest drop in opioid prescriptions,” Work referenced by Harrison Cook for *Becker’s Hospital Review*. June 19, 2018. Available at: <https://www.beckershospitalreview.com/opioids/these-4-states-saw-the-biggest-drop-in-opioid-prescriptions.html>.
52. “Behind schedule – reconciling federal and state marijuana policy,” Work cited by Douglas Berman for *Marijuana Law, Policy & Reform*. July 13, 2018. Available at: http://lawprofessors.typepad.com/marijuana_law/2018/07/behind-schedule-reconciling-federal-and-state-marijuana-policy.html.
53. “Implications of the Divide between Federal and State Marijuana Policy,” Interviewed for Video by University of Michigan School of Public Health. July 16, 2018. Available at: <https://youtu.be/IIUJDJ3p7ls>.
54. “Sex, Drugs, and Civil Liberties,” Radio interview KOPN Columbia Missouri 89.5 FM show by host, Dan Viets, to discuss state and federal marijuana policy. July 17, 2018.
55. “Mental health parity law associated with financial protection for children,” Work referenced by *2 Minute Medicine*. July 23, 2018. Available at: <https://www.2minutemedicine.com/mental-health-parity-law-associated-with-financial-protection-for-children/>.
56. “Marijuana’s uncertain stats: closing the gap between state and federal policies,” Work cited by Laurel Ranger for *Medical Bag*. Aug. 7, 2018. Available at: <https://www.medicalbag.com/policy/state-federal-marijuana-policy-gap/article/786479/>.
57. “Interview with Dr. Rebecca Haffajee on reconciling federal and state marijuana policy,” *New England Journal of Medicine*. Aug. 8, 2018. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMp1804408>.
58. “Pot legalization advocates seek foothold in Midwest states,” Interview by David Eggert for Associated Press article published in *The New York Times, The Washington Post, U.S. News & World Report, The Detroit News, Fox Business, ABC News, Houston Chronicle, Miami Herald, Chicago Tribune*. Oct. 9, 2018. Available at <https://www.nytimes.com/aponline/2018/10/09/us/ap-us-election-2018-marijuana.html>.
59. “One year after Trump declared opioid addiction a public-health emergency, what’s changed?” Interviewed by Francie Diep for *Pacific Standard*. Oct. 25, 2018. Available at <https://psmag.com/news/one-year-after-trump-declared-opioid-addiction-a-public-health-emergency-whats-changed>.
60. “China has promised to crack down on fentanyl. Here’s what that could mean for overdose deaths in the U.S.,” Interviewed by Jaimie Ducharme for *Time*, Dec. 3, 2018. Available at: <http://time.com/5469231/china-fentanyl-controlled-substance/>.

61. "Impact of Michigan's marijuana law," Interviewed by Jorge Avellan for *WEMU* radio (National Public Radio station), Dec. 6, 2018.
62. "What drives patients to use medical marijuana: Mostly chronic pain," Work cited in *Science Daily*, Feb. 4, 2019. Available at: <https://www.sciencedaily.com/releases/2019/02/190204172220.htm>.
63. "Evidence for addressing the opioid epidemic: rounding out the evidence," Work cited by Colleen Barry and Richard Frank in *Brookings Institution Blog*, Feb. 6, 2019. Available at: <https://www.brookings.edu/blog/up-front/2019/02/06/evidence-for-addressing-the-opioid-epidemic-rounding-out-the-picture/>.
64. "What Oklahoma's \$270 million settlement with Purdue Pharma means for the 1,000-plus opioid cases still pending," Interviewed by Francie Diep for *Pacific Standard*. Mar. 27, 2019. Available at: <https://psmag.com/news/what-oklahomas-settlement-with-purdue-pharma-means-for-opioid-cases>.
65. "Smoking pot vs. tobacco: What science says about lighting up," Interviewed by Jennifer Peltz for Associated Press article published in *Chicago Tribune*, *Houston Chronicle*, *San Francisco Chronicle*, *Washington Post*, *ABC News*, *Omaha-World Herald*, *NBC Chicago*, *U.S. News & World Report*, *The Detroit News*. April 7-8, 2019. Available at: <https://www.chicagotribune.com/lifestyles/health/ct-cb-smoking-pot-vs-tobacco-20190408-story.html>.
66. "Don't just blame drug companies for the opioid epidemic," Presentation quoted by Joyce Friedan in *MedPage Today*, April 14, 2019. Available at: <https://www.healthleadersmedia.com/dont-just-blame-drug-companies-opioid-crisis>.
67. "University of Michigan and Harvard hold joint summit on opioid crisis," Quoted by Jacob Hamilton in *MLive*, May 10, 2019. Available at: <https://www.mlive.com/news/ann-arbor/2019/05/university-of-michigan-harvard-team-up-to-tackle-opioid-crisis.html>.
68. "University of Michigan, Harvard team up to tackle opioid crisis," Quoted by Martin Slagter in *MLive*, May 10, 2019. Available at: <https://www.mlive.com/news/ann-arbor/2019/05/university-of-michigan-harvard-team-up-to-tackle-opioid-crisis.html>.
69. "Opioid doctor and pharmacy 'shoppers' may also shop at home, study suggests," Work cited by Kara Gavin in *University of Michigan News*, May 10, 2019. Available at: <https://news.umich.edu/opioid-doctor-and-pharmacy-shoppers-may-also-shop-at-home-u-m-study-suggests/>.
70. "Responses To The Opioid Epidemic Vary Across The Country — But A Few Themes Stand Out," Interviewed by Celia Darrough & Paige Tartorelli for *Bustle*, June 5, 2019. Available at: <https://www.bustle.com/p/responses-to-the-opioid-epidemic-vary-across-the-country-but-a-few-themes-stand-out-17939248>.
71. "How an American billionaire predicted — and then profited from — an Oxycontin 'prescription blizzard'," Quoted by Adrianna Belmonte for *Yahoo Finance*, June 12, 2019. Available at: <https://finance.yahoo.com/news/opioid-crisis-purdue-sacklers-141623926.html>.
72. "Opioids study shows high-risk counties across the country, suggests local solutions to epidemic," Study profiled by Nardy Baeza Bickel in *University of Michigan News*, June 28, 2019. Available at: <https://news.umich.edu/opioids-study-shows-high-risk-counties-across-the-country-suggests-local-solutions-to-epidemic/>.

73. "24 Michigan counties are at 'high-risk' in the national opioid epidemic," Interviewed by Stateside Staff in *Michigan Radio National Public Radio*, July 10, 2019. Available at: <https://www.michiganradio.org/post/24-michigan-counties-are-high-risk-national-opioid-epidemic>.
74. "A graphic look at the opioid epidemic," Interviewed by the Jefferson Exchange Team for *Jefferson Public Radio*, July 11, 2019. Available at: <https://www.ijpr.org/post/graphic-look-opioid-epidemic#stream/0>.
75. "Drug overdose deaths in the U.S. appear to be falling, CDC data show," Interviewed by Mike Stobbe for Associated Press article published in *LA Times*, *New York Times*, *Washington Post*, *MarketWatch*, *U.S. News & World Reports*, *Washington Times*, *Seattle Times*, *ABCnews*, *Yahoo News*, *Fox News*, *WebMD*, etc. July 17, 2019. Available at: <https://www.latimes.com/science/story/2019-07-17/us-drug-overdose-deaths-falling>.
76. "Federal government pledges millions for opioid crisis," Quoted by the Canadian Press for *CBC*, July 17, 2019. Available at: <https://www.cbc.ca/news/health/opioid-crisis-1.5215690>.
77. "Livingston county at 'high-risk' for opioid overdoses, study says," Study profiled by Sean Bradley for *Livingston Daily*, July 17, 2019. Available at: <https://www.livingstondaily.com/story/news/local/community/livingston-county/2019/07/17/livingston-county-high-risk-opioid-overdoses-study-says/1734891001/>.
78. "Forty-one N.C. counties classified as 'high-risk' in new opioid study," Interviewed by Yen Duong for *North Carolina Health News*, July 23, 2019. Available at: <https://www.northcarolinahealthnews.org/2019/07/23/41-nc-high-risk-medication-assisted-treatment/>.
79. "Why aren't more people with opioid use disorder getting buprenorphine? 2 experts discuss ways to expand access to this effective drug," Interview with PEW Charitable Trusts, July 31, 2019. Available at: <https://www.pewtrusts.org/en/research-and-analysis/articles/2019/07/31/why-arent-more-people-with-opioid-use-disorder-getting-buprenorphine>.
80. "New details about Michigan's opioid crisis: Billions of pills and aggressive suppliers," Quoted by Julie Mack & Scott Levin in *MLive*, Aug. 12, 2019. Available at: <https://www.mlive.com/news/2019/08/new-details-about-michigans-opioid-crisis-billions-of-pills-and-aggressive-suppliers.html>
81. "Average Michigan opioid patient got 62-day supply in 2018. CDC standard is less than a week," Quoted by Julie Mack & Scott Levin in *MLive*, Aug. 18, 2019. Available at: <https://www.mlive.com/news/2019/08/average-michigan-opioid-patient-got-62-day-supply-in-2018-cdc-standard-is-less-than-a-week.html>.
82. "Healthcare policy researcher: State PDMPs need to be tweaked to improve functionality, safeguard privacy," Work cited by Mark Hagland in *Healthcare Innovation*, Aug. 21, 2019. Available at: <https://www.hcinnovationgroup.com/policy-value-based-care/public-health/news/21093784/healthcare-policy-researcher-state-pdmps-need-to-be-tweaked-to-improve-functionality-safeguard-privacy>.
83. "Cannabis: A Silver Bullet for the Opioid Crisis?" Interviewed by Jaime Santa Cruz in *CRx Magazine*, Fall 2019. Available at: <https://www.crxmag.com/issues/2019/fall/cannabis-a-silver-bullet-for-the-opioid-crisis.shtml>.
84. "How States Are Holding Opioid Manufacturers and Distributors Accountable," Interviewed for *The Takeaway* for WNYC Studios (produced by Public Radio International and WGBH and WNYC Studios), Sept. 11, 2019. Available at: <https://www.wnycstudios.org/podcasts/takeaway/segments/opioid-crisis-drug-manufacturers-and-distributors>.

85. “The opioid epidemic reckoning is happening – kind of,” Interviewed by Adriana Belmonte for *Yahoo Finance*, Sept. 11, 2019. Available at: <https://finance.yahoo.com/news/opioid-settlement-sackler-200905914.html>.
86. “Did Kentucky get duped in its Purdue Pharma settlement? Or did politics play a part?” Interviewed by Phillip M. Bailey for *Louisville Courier Journal*, Sept. 20, 2019. <https://www.courier-journal.com/story/news/politics/2019/09/20/kentucky-one-of-first-lawsuits-against-purdue-pharma-oxycotin-maker-was-settlement-enough/2311276001/>
87. “The (Human) Cost of Greed,” Interviewed by James Strachan for *The Medicine Maker*, Nov. 27, 2019. <https://themedicinemaker.com/business-regulation/the-human-cost-of-greed>
88. “Opioid-treatment maker again accused of anti-competitive practices,” Interviewed by Marty Schladen for *The Columbus Dispatch*, Jan. 9, 2020. <https://www.dispatch.com/news/20200109/opioid-treatment-maker-again-accused-of-anti-competitive-practices>
89. “NEJM Perspective: Congress Needs to Help FDA Combat Procedural Abuses,” Quoted by Zachary Brennan for *Regulatory Focus*, Jan. 9, 2020. <https://www.raps.org/news-and-articles/news-articles/2020/1/nejm-perspective-congress-needs-to-help-fda-comba>
90. “FDA to Pull Nearly 250 ANDAs, Continues to Revamp OND,” Quoted by Alex Keown for *BioSpace*, Jan. 10, 2020. <https://www.biospace.com/article/fda-to-pull-nearly-250-andas-continues-to-revamp-ond/>
91. “Federalism meets the COVID-19 pandemic: thinking globally, acting locally,” Quoted by Beth Duff-Brown for *Stanford Health Policy CHP/PCOR News*, Apr. 2, 2020. <https://healthpolicy.fsi.stanford.edu/news/federalism-meets-covid-19-pandemic-thinking-globally-acting-locally>
92. “U.S. federal government missed opportunity to fight Covid-19: U.S. journal,” Quoted by She Jingwei for *CGTN*, Apr. 5, 2020. <https://news.cgtn.com/news/2020-04-04/U-S-federal-government-missed-opportunity-to-fight-COVID-19-NEJM-PqaTygbDIC/index.html>
93. “Coronavirus: as government feud, researchers, scientists and tech firms fill collaborative void in search for cure,” Interviewed by Jodi Xu Klein for *South China Morning Post*, Apr. 9, 2020. <https://www.scmp.com/news/china/article/3079081/coronavirus-governments-feud-researchers-scientists-and-tech-firms-fill>
94. “Could your cellphone data be used to enforce stay-at-home orders?” Interviewed by Lauren Rosenblatt for *Pittsburgh Post-Gazette*, Apr. 14, 2020. <https://www.post-gazette.com/business/tech-news/2020/04/12/privacy-surveillance-cellphone-location-tracking-data-Google-Unacast-coronavirus/stories/202004090143>
95. “Drug companies face lawsuits from opioid crisis as they respond to the pandemic,” Interviewed by Brian Mann for *All Things Considered*, Aug. 7, 2020. <https://www.wkms.org/post/drug-companies-face-lawsuits-opioid-crisis-they-respond-pandemic#stream/0>
96. “Opioid scandal haunts drug companies as they respond to pandemic,” Interviewed by Brian Mann for *National Public Radio*, Aug. 10, 2020. <https://www.ideastream.org/news/opioid-scandal-haunts-drug-companies-as-they-respond-to-pandemic>

97. “The opioid crisis is 'a unique product' of U.S. health care, paper argues,” Quoted by Adriana Belmonte for *Yahoo Finance*, Aug. 29, 2020. <https://finance.yahoo.com/news/opioid-crisis-health-care-system-165837992.html>
98. “Reimagining the sharing of government authority in the time of Covid,” Work quoted by Gregg Girvan for *The Fulcrum*, Sept. 10, 2020. <https://thefulcrum.us/balance-of-power/national-government-powers>
99. “California insurers brace for new mental health coverage law,” Quoted by Tiffany Stecker for *Bloomberg Law*, Sept. 24, 2020. <https://news.bloomberglaw.com/health-law-and-business/california-insurers-brace-for-new-mental-health-coverage-law>
100. “As more students head back, here’s what we now know (and still don’t) about schools and COVID spread,” Interviewed by Matt Barnum for *Chalkbeat*, Oct. 22, 2020. <https://www.chalkbeat.org/2020/10/22/21528835/schools-covid-spread-research-questions>
101. “Why Reopening Schools Has Become the Most Fraught Debate of the Pandemic,” Interviewed by Rachel Cohen for *The American Prospect*, Oct. 28, 2020. <https://prospect.org/coronavirus/why-reopening-schools-has-become-the-most-fraught-debate-of-the-pandemic/>

SELECTED PRESENTATIONS:

- 2013 “Impact of Mental Health Parity Laws on Costs, Service Utilization, and Health Outcomes,” PhD in Health Policy Research Seminar, Department of Health Care Policy, Harvard Medical School, Boston, MA.
- 2014 “Impact of Parity Laws on Mental Health Treatment and Outcomes,” Robert Wood Johnson Foundation Public Health Law Research Program Annual Meeting, Atlanta, GA. (podium presentation)
- 2014 “Impact of the 2008 Federal Parity Law on Mental Health Care Utilization,” Pharmaceutical Policy Research Seminar, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA.
- 2015 “Impact of Prescription Drug Monitoring Programs on Use and Abuse of Prescription Drugs,” Pharmaceutical Policy Research Seminar, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA.
- 2015 “Prescription Drug Monitoring: Promise or Predicament,” Health Policy Grand Rounds Invited Speaker, Lawrence Memorial Hospital Campus, Hallmark Health System, Lawrence, MA.
- 2015 “Impact of Federal Mental Health Parity on Mental Health Use and Spending,” Department of Population Medicine Brown Bag Lunch Seminar, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA.
- 2015 “Impact of Federal Mental Health Parity on Mental Health Care Use and Spending,” AcademyHealth Annual Research Meeting, Minneapolis, MN. (poster presentation)
- 2016 “Opioid Addiction: Legal and Public Health Responses,” Harvard Law School Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics Year in P/Review Conference, Cambridge, MA. (podium presentation)
- 2016 “Empirical Health Law,” Harvard Law School Petrie Flom Center for Health Law Policy Biotechnology, and Bioethics 10th Anniversary Conference, Cambridge, MA. (panelist)

-
- 2016 “Effects of Robust State Prescription Drug Monitoring Programs on Opioid Prescribing and Use,” Pharmaceutical Policy Research Seminar, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA.
- 2016 “Effects of Robust State Prescription Drug Monitoring Programs on Opioid Prescribing and Use,” 39th Annual ASLME Health Law Professors Conference, Boston University School of Law, Boston, MA. (podium presentation)
- 2016 “Evaluating Legal Interventions Designed to Improve Behavioral Health Outcomes,” PhD Program in Health Policy Dissertation Defense, Harvard University, Boston, MA.
- 2016 “Evaluating Legal Interventions Designed to Improve Behavioral Health Outcomes,” Mental Health Innovation, Services and Outcomes Program Invited Speaker, University of Michigan, Ann Arbor, MI.
- 2016 “The Opioid Epidemic: Origins and Policy Responses,” Griffith Leadership Center Virtual Alumni Forum Invited Speaker, University of Michigan School of Public Health, Ann Arbor, MI.
- 2017 “The Effect of Robust Prescription Drug Monitoring Programs on Opioid Prescribing Outcomes,” 8th Annual Empirical Health Law Conference, Boston University School of Law, Boston, MA. (podium presentation)
- 2017 “Policy Strategies to Curb the Opioid Epidemic: The Role of Prescription Drug Monitoring Programs,” Health Policy & Management Research Seminar Invited Speaker, Indiana University Fairbanks School of Public Health, Indianapolis, IN.
- 2017 “Pandora’s Box: The (Unknown) Consequences of Legalizing Marijuana Use,” Law Students for Sensible Drug Policy Seminar Invited Speaker, University of Michigan Law School, Ann Arbor, MI.
- 2017 “Using the Law to Ramp-Up Medication Assisted Treatment Therapy,” 40th Annual ASLME Health Law Professors Conference, Georgia State University College of Law, Atlanta, GA. (podium presentation)
- 2017 “The Effect of Robust Prescription Drug Monitoring Programs on Opioid Prescribing Outcomes,” AcademyHealth Annual Research Meeting, New Orleans, LA. (podium presentation)
- 2017 “Prescription Drug Monitoring Programs: Policy Landscape & Best Practices,” Institute for Healthcare Policy and Innovation & M-OPEN, Injury Prevention Center Event Invited Speaker, Ann Arbor, MI
- 2017 “The State of Michigan’s Opioid Epidemic: Origins and Impact,” Council of Michigan Foundations Invited Speaker, Ann Arbor, MI.
- 2017 “The Effect of Robust Prescription Drug Monitoring Programs on Opioid Prescribing Outcomes,” SAVIR Conference, Ann Arbor, MI. (podium presentation)
- 2017 “Policy Approaches to the Opioid Crisis,” USC-Brookings Schaeffer Initiative for Health Policy, The Brookings Institution, Washington, DC. (panelist)
- 2018 “Monitoring and Regulating Prescribing to Mitigate the Opioid Epidemic,” The Institute for Continuing Legal Education, 24th Annual Health Law Institute, Plymouth, MI. (podium presentation)
- 2018 “Using the Law to Tackle the Opioid Crisis,” Theodore R. LeBlang Distinguished Lectureship in Law & Medicine, Southern Illinois University School of Medicine, Springfield, IL. (podium presentation)

-
- 2018 “Characterizing U.S. Counties with High Opioid Overdose and Low Medication-Assisted Treatment Supply,” 41st Annual ASLME Health Law Professors Conference, Case Western Reserve University School of Law, Cleveland, OH. (podium presentation)
- 2018 “Behavioral Health Workforce Implementation Challenges Related to Medication Assisted Treatment,” AcademyHealth Annual Research Meeting, Seattle, WA. (poster presentation)
- 2018 “Characterizing U.S. Counties with High Opioid Overdose and Low Medication-Assisted Treatment Supply,” AcademyHealth Annual Research Meeting, Seattle, WA. (poster presentation)
- 2018 “Characterizing U.S. Counties with High Opioid Overdose and Low Medication-Assisted Treatment Supply,” AcademyHealth Annual Research Meeting, Behavioral Interest Group Meeting, Seattle, WA. (podium presentation)
- 2018 “Building Successful Careers in Academia,” AcademyHealth Annual Research Meeting, Seattle, WA. (podium presentation & panelist)
- 2018 “Emerging Approaches to Monitoring the Opioid Epidemic and its Impact,” AcademyHealth Annual Research Meeting, Seattle, WA. (moderator)
- 2018 “Civil Drug Crisis in the United States,” Speaker at Facing Opioids Symposium, Ohio State Law Journal Annual Symposium, Columbus, OH. (podium presentation & panelist)
- 2018 “Policy Approaches to Addressing the Opioid Crisis,” Keynote speaker, 2nd Annual Addiction Conference, SUNY Upstate, Syracuse, NY. (podium presentation & panelist)
- 2018 “Opioid Prescribing Policy Impacts,” University of Michigan Dental School Invited Speaker, Ann Arbor, MI. (podium presentation)
- 2018 “The Opioid Epidemic: States and Cities Strike Back,” Speaker/panelist for American Bar Association Webinar. (presentation & panelist)
- 2019 “State Opioid Policy & Impacts,” Invited Speaker at Wolverine Caucus, Lansing, MI. (podium presentation)
- 2019 “The Role of Litigation in Mitigating the Opioid Crisis,” 25th Annual Thomas Pitts Lectureship in Medical Ethics, Medical University of South Carolina, Charleston, SC. (podium presentation & panelist)
- 2019 “Public Policy & the Opioid Epidemic” Invited Speaker at American College of Physicians Internal Medicine 2019 Annual Meeting, Philadelphia, PA. (podium presentation & panelist)
- 2019 “Opioids: Policy to Practice” Invited Speaker at University of Michigan/Harvard Summit, Ann Arbor, MI. (panelist)
- 2019 “Generic Drug Policy as a Barrier to Opioid Use Disorder Treatment,” 42nd Annual ASLME Health Law Professors Conference, Loyola University Chicago School of Law, Chicago, IL. (podium presentation)
- 2019 “The Opioid Overdose Crisis: States and Localities Fight Back Using Litigation,” Michigania Faculty Forum, Boyne City, MI. (podium presentation)
- 2019 “Public Health Law Approaches to Addressing the Opioid Crisis: Intended and Unintended Consequences,” Michigania Faculty Forum, Boyne City, MI. (podium presentation)

- 2019 “Congressional Staff Briefing on Barriers to Substance Use Treatment,” Cannon House Office Building, Washington, DC. (panelist)
- 2020 “Dying to Live: Halting Overdose Deaths,” South by Southwest Conference, Austin, TX. (panelist speaker) – conference cancelled due to Covid-19
- 2020 “Government Opioid Litigation: The Reasonable Bounds of Liability,” Clifford Symposium, DePaul University College of Law, Chicago, IL. (invited speaker)
- 2020 “Spicy Debate: X the X Waiver?” 44th AMERSA Annual Conference, Virtual. (moderator)
- 2020 “What Makes Opioid Litigation Different from Other Mass Torts?” RAND Corporation Institute for Civil Justice Board Meeting, Virtual. (moderator & speaker)
- 2020 “An Empirical Look at the Opioid Litigation” Program on Regulation, Therapeutics, and Law, Harvard Medical School. (invited speaker)